Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

Biomimetic antimicrobial peptide inspired by insects to combat multi-drug-resistant Acinetobacter baumannii

Ziel

OMN6 is a synthetic cyclic peptide developed to treat infections caused by multidrug resistant A. baumannii, a WHO critical priority pathogen linked to high mortality. After a clean Phase 1 and an ongoing Phase 2, PEPTAMR moves OMN6 toward late clinical development with the goal of delivering a regulatory-ready Phase 3 package
The project will expand clinical data collection across Europe, complete the preclinical work needed to justify dosing and indications, run a healthy-volunteer lung penetration study, and finalise a stable, scalable clinical formulation ready for manufacturing. A companion diagnostic roadmap will be prepared to help clinicians identify patients who can benefit most.
Led by OMN with VIV, MUV, NKUA and ECR, PEPTAMR combines industry and academic strengths to produce the assays, models and clinical evidence that will enable licensing and broad hospital use. The ultimate aim is to provide hospitals with a safe, effective, and practical therapy for a deadly, hard to treat pathogen.

Wissenschaftliches Gebiet (EuroSciVoc)

Schlüsselbegriffe

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-RIA - HORIZON Research and Innovation Actions

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) HORIZON-HLTH-2025-01

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Koordinator

OMNIX MEDICAL LTD
Netto-EU-Beitrag
€ 4 943 800,00
Adresse
RACAH 1
9270401 JERUSALEM
Israel
KMU
Ja
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Gesamtkosten
€ 4 943 800,00

Beteiligte (4)